Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 343,754,240
  • Shares Outstanding, K 6,370,538
  • Annual Sales, $ 70,874 M
  • Annual Income, $ 9,402 M
  • EBIT $ 0 M
  • EBITDA $ 19,129 M
  • 60-Month Beta 0.44
  • Price/Sales N/A
  • Price/Cash Flow 16.15
  • Price/Book 8.48
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/29/26 [--]
  • Annual Dividend & Yield (Fwd) 0.87 (1.64%)
  • Most Recent Dividend 0.873 on 03/28/25
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.32
  • Number of Estimates 1
  • High Estimate 1.32
  • Low Estimate 1.32
  • Prior Year N/A
  • Growth Rate Est. (year over year) -99.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.5100 +9.31%
on 12/17/25
54.5150 -0.72%
on 01/15/26
+2.9000 (+5.66%)
since 12/15/25
3-Month
40.0700 +35.06%
on 11/03/25
54.5150 -0.72%
on 01/15/26
+9.6400 (+21.67%)
since 10/15/25
52-Week
34.7500 +55.74%
on 04/09/25
54.5150 -0.72%
on 01/15/26
+17.6200 (+48.27%)
since 01/15/25

Most Recent Stories

More News
Looking to ‘Sell America’ Amid Fed Drama? Here’s 1 ETF to Buy.

'Sell America' fear is rising again, and this non-U.S. ETF could be a wise buy to stay diversified and invested globally while U.S. policy risks swirl.

BLK : 1,156.65 (+5.93%)
BABA : 170.93 (+0.61%)
DXY00 : 99.347 (+0.29%)
SIH26 : 92.335 (+1.04%)
GCG26 : 4,619.4 (-0.35%)
NVS : 143.15 (-2.06%)
RHHBY : 54.1200 (+0.30%)
HSBC : 82.83 (+1.31%)
TSM : 341.64 (+4.44%)
ASML : 1,331.60 (+5.37%)
$DXY : 99.35 (+0.29%)
AZN : 93.99 (-2.44%)
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology

Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from...

AZN : 93.99 (-2.44%)
PPCB : 0.3513 (-17.13%)
RHHBY : 54.1200 (+0.30%)
BMY : 56.62 (-0.70%)
FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

– Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute – – Availability of Lunsumio VELO allows treatment aligned to people’s clinical...

RHHBY : 54.1200 (+0.30%)
Genentech Announces Agreement With U.S. Government

– Agreement with the U.S. government addresses prescription drug costs and encourages other wealthy nations to reward biopharmaceutical innovation – – Influenza...

RHHBY : 54.1200 (+0.30%)
Roche announces U.S. launch of next-generation cobas 6800/8800 systems and software, enhancing laboratory efficiency and testing capabilities

INDIANAPOLIS , Dec. 16, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the new cobas ® 6800/8800 systems version 2.0 and software version 2.0.1,...

ROG : 100.89 (+1.24%)
RHHBY : 54.1200 (+0.30%)
Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer

– Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years – ...

RHHBY : 54.1200 (+0.30%)
Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas

– Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-arm cohort of Phase III CELESTIMO study –...

RHHBY : 54.1200 (+0.30%)
Olema Pharmaceuticals Has Nearly Tripled on Cancer Drug Hopes. How Should You Play OLMA Stock Here?

Olema stock soared Tuesday after Roche reported strong clinical results for its breast cancer drug. An Oppenheimer analyst sees significant further upside in OLMA shares to $45.

OLMA : 29.19 (+1.46%)
RHHBY : 54.1200 (+0.30%)
Genentech’s Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer

-At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit versus standard-of-care endocrine monotherapy- -These unprecedented...

RHHBY : 54.1200 (+0.30%)
Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche

BASEL, Switzerland , Nov. 12, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today research findings showing that 31% of eligible millennials have postponed or missed their cervical...

ROG : 100.89 (+1.24%)
RHHBY : 54.1200 (+0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its...

See More

Key Turning Points

3rd Resistance Point 54.5967
2nd Resistance Point 54.3333
1st Resistance Point 54.1467
Last Price 54.1200
1st Support Level 53.6967
2nd Support Level 53.4333
3rd Support Level 53.2467

See More

52-Week High 54.5150
Last Price 54.1200
Fibonacci 61.8% 46.9648
Fibonacci 50% 44.6325
Fibonacci 38.2% 42.3002
52-Week Low 34.7500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar